Women's football star benefits on and off the
pitch from EVO ICL™ vision correction procedure
LONDON, Nov. 4, 2024
/PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a
leading developer, manufacturer, and marketer of the EVO family of
Implantable Collamer® lenses (EVO ICL™) for myopia,
astigmatism and presbyopia, is proud to announce a collaboration
with women's international football player Lucy Bronze, MBE. She's
gained global recognition as a "serial winner" and has now chosen a
winning strategy by selecting STAAR Surgical to improve her vision
with leading vision correction procedure: EVO ICL.
Bronze has won five Champions League titles and has been one of
her country's strongest performers since her senior team debut in
2013. Since then, she's won every domestic football honor in her
country during spells with several teams, and she has also lived
abroad to play for clubs in other countries. In addition, Bronze
was named the 2018/19 UEFA Women's Player of the Year and The
Best FIFA Women's Player for 2020.
"I've won the Euros and five champions leagues, but I always had
that worry on the pitch that my contact lenses might fall out, and
mid-game, it has actually happened. Not to mention the dry eyes,
uncomfortable lens fits and daily hassles," said Bronze. "I
realised I needed to tackle my vision. EVO ICL has been a procedure
that changed my life completely, and my biggest regret is literally
the fact that I didn't do it sooner."
EVO ICL is great for patients who are tired of the hassles of
glasses and contacts and want to upgrade their vision with a quick,
easy, and long-term vision correction solution. The EVO ICL
procedure is a same-day surgery, so patients are typically back to
their usual routines without delay.
Tom Frinzi, President and CEO of
STAAR Surgical, states, "Lucy Bronze is a champion on the football
pitch, and we are proud to have her as the newest champion of EVO
ICL. STAAR's innovative EVO ICL procedure has changed her eyesight,
her game, and her life."
EVO ICL is a clinically proven implantable lens that treats
patients with mild to severe shortsightedness (myopia) with or
without astigmatism. With EVO ICL, the natural lens remains intact.
A small, soft, biocompatible lens, EVO ICL is positioned inside the
eye, between the iris (coloured part of the eye) and the natural
lens. The procedure is usually completed in 20-30 minutes and does
not induce dry eye syndrome. 1,2
EVO ICL has been approved, marketed, and successfully implanted
by ophthalmologists in countries throughout Europe, North
America, Asia, and the rest
of the world. According to a STAAR patient survey, 99.4% of
patients would have the EVO ICL procedure again.3 Over
3,000,000 ICLs have been distributed globally.
For more information about EVO Implantable Collamer Lenses,
please visit https://evoicl.com.
References:
- Zhang H, Deng Y, Ma K, Yin H, Tang J. Analysis on the changes
of objective indicators of dry eye after implantable collamer lens
(ICL) implantation surgery. Graefes Arch Clin Exp Ophthalmol. 2024
Jul;262(7):2321-2328.
- Naves J.S, Carracedo G, Cacho-Babillo I, Diadenosine
nucleotid measurements as dry-eye score in patients after LASIK and
ICL surgery. Presented at American Society of Cataract and
Refractive Surgery (ASCRS) 2012.
- Packer M. The Implantable Collamer Lens with a central
port: review of the literature. Clin Ophthalmol. 2018: 12:
2427–2438.
About STAAR Surgical
STAAR, which has been dedicated solely to ophthalmic surgery for
over 40 years, designs, develops, manufactures, and markets
implantable lenses for the eye. These lenses are intended to
provide visual freedom for patients, lessening or eliminating the
reliance on glasses or contact lenses. All these lenses are
foldable, which permits the surgeon to insert them through a small
incision. STAAR's lens used in refractive surgery is called an
Implantable Collamer® Lens or "ICL," which includes the
EVO ICL™ product line. More than 3,000,000 ICLs have been sold to
date and STAAR markets these lenses in over 75 countries. To learn
more about the ICL go to: www.evoicl.com. Headquartered in
Lake Forest, CA, the company
operates manufacturing and packaging facilities in Aliso Viejo, CA, Monrovia, CA and Nidau, Switzerland. For more information, please
visit the Company's website at www.staar.com.
Important Safety Information for EVO/EVO+ ICL
Implantation of the EVO/EVO+ ICL is a surgical procedure, and as
such, carries potentially serious risks. The EVO/EVO+ ICL is
designed for the correction/reduction of up to -20 diopters (D) of
nearsightedness with up to 6 D of astigmatism for patients who are
21 to 60 years of age. Before considering EVO/EVO+ ICL surgery you
should have a complete eye examination and talk with your eye care
professional about the procedure, especially the potential
benefits, risks, and complications. You should discuss the time
needed for healing after surgery. For additional information with
potential benefits, risks and complications please visit
DiscoverICL.com.
Media Contact
5W Public Relations
EVO@5wpr.com
Logo -
https://mma.prnewswire.com/media/2537233/EVO_ICL_Evolution_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/staar-surgical-and-lucy-bronze-mbe-see-eye-to-eye-on-vision-correction-302283504.html